Precision BioSciences Stock (NASDAQ: DTIL)

Precision BioSciences (NASDAQ:DTIL) Stock, Quote.Headers.trade-ideas

Precision BioSciences

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACIC

ADIL

ARVN

BIVI

CRDF

DCFC

DELL

DMTK

DTIL

ESTC

EVBG

GRTS

HLTH

HUMA

JAGX

JAKK

LIFW

MINM

NTAP

NYCB

OPRA

RDNT

REAL

RGNX

RILY

RMBS

ROOT

RPAY

SANA

SCLX

SENS

SIDU

SOUN

TTEC

VANI

VLCN

VTYX

XPOF

YMAB

Shares of  Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Equities

Mid Cap

Guidance

TGTX

TG Therapeutics Inc (NASDAQ: TGTX) reported preliminary BRIUMVI U.S. 

Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?

Precision BioSciences, Inc. (NASDAQ: DTIL) shares are trading higher Tuesday after the company announced it has signed a licensing agreement wit

Why Precision BioSciences Stock Is Up Today

Precision BioSciences, Inc. - Common Stock

Precision BioSciences Inc

CLEAR Expands TSA PreCheck Enrollment And Renewal Services With Four New Locations, Including San Antonio And Buffalo Niagara Airports; Now Operating At 51 U.S. Locations

<ul>
<li>U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025</li>
<li>Almost half of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp</li>
<li>Supplemental New Drug Application (sNDA) supported by positive efficacy and safety data from Phase 2b and pivotal Phase 3 trials, and long-term ZORYVE cream plaque psoriasis program<br /><br />&nbsp;</li>
</ul>
<p>WESTLAKE VILLAGE, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KIeqveaDQX7yDbtQmBYbYGS60zB7UAImm5fncsFaGQRGkqjxKDJJj88exm7xues1TD0CzdcQ9Z9oFnKZaVdwYA_o-UuMhRo1cdu5-Sbcf7k=">Arcutis Biotherapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis. The FDA assigned the application a PDUFA target action date of May 22, 2025.</p>


Biotech

General

ARQT

FDA Accepts Arcutis' Supplemental New Drug Application For ZORYVE Foam For The Treatment Of Scalp And Body Psoriasis In Adults And Adolescents Ages 12 and Over

<p>Benchmark  analyst Josh Sullivan   reiterates AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) with a Buy and maintains $83 price target.</p>


Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Buy on AAR, Maintains $83 Price Target

<p><i>NetApp's end-to-end enterprise AI vision and intelligent ONTAP data infrastructure—combined with powerful NVIDIA NeMo Retriever and NIM microservices—transform how customers discover, search and curate data across hybrid multi-cloud to fuel AI applications</i></p>
<p>NetApp&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>), the intelligent data infrastructure company, today unveiled an advanced generative AI data vision and end-to-end integrated solutions that combine NVIDIA AI software and accelerated computing with NetApp intelligent data infrastructure for enterprise retrieval augmented generation (RAG) to power the future of agentic AI applications.</p>
<p>This will bring new capabilities to the NetApp ONTAP unified storage operating system that can leverage a new <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.netapp.com%2Fnewsroom%2Fpress-releases%2Fnews-rel-20240924-943497%2F&amp;esheet=54126360&amp;newsitemid=20240924466639&amp;lan=en-US&amp;anchor=NetApp+global+metadata+namespace&amp;index=1&amp;md5=ef1570577254f5dc715de4a2bb01c44d">NetApp global metadata namespace</a> to unify data stores for the tens of thousands of enterprises that trust NetApp for their data infrastructure. It opens up exabytes of enterprise data stored across clouds and on-premises infrastructure to drive RAG capabilities that can put enterprises' entire data estate to work, accelerating next-generation agentic AI applications.</p>
<p>The solution brings together proven NetApp AIPod architecture with NetApp ONTAP and the NetApp BlueXP unified control plane, with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2Fai-data-science%2Fproducts%2Fnemo%2F&amp;esheet=54126360&amp;newsitemid=20240924466639&amp;lan=en-US&amp;anchor=NVIDIA+NeMo+Retriever&amp;index=2&amp;md5=d3208f897b7f0b9d5735b944f3ce9919">NVIDIA NeMo Retriever</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2Fai%2F&amp;esheet=54126360&amp;newsitemid=20240924466639&amp;lan=en-US&amp;anchor=NIM+microservices&amp;index=3&amp;md5=58fc0dbe2824fbb832a0d5d3360749b5">NIM microservices</a>, which are part of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2Fdata-center%2Fproducts%2Fai-enterprise%2F&amp;esheet=54126360&amp;newsitemid=20240924466639&amp;lan=en-US&amp;anchor=NVIDIA+AI+Enterprise&amp;index=4&amp;md5=a78b65af21f74b6ba2e5e4437f315d98">NVIDIA AI Enterprise</a> software platform.</p>


NVDA

NetApp Teams With NVIDIA To Redefine Enterprise Retrieval Augmented Generation And Power Agentic AI

Management

PPG Names Kevin Braun Senior VP Of Operations Effective October 1, 2024, Succeeding Ram Vadlamannati Who Will Retire After 25 Years; Braun To Oversee Operations, Supply Chain, And Coatings

<p><i>Growth of HPE Aruba Networking Central customer base and data lake accelerates better AI insights and improved network management, security, performance and visibility</i></p>
<p>Hewlett Packard Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) today announced the expansion of HPE Aruba Networking Central, its security-first, AI-powered network management solution, with new AI insights and capabilities that include integration of OpsRamp for third-party network device monitoring of industry vendors such as Cisco, Juniper Networks, and Palo Alto Networks.</p>
<p>New capabilities of HPE Aruba Networking Central also include an improved network device configuration engine, expanded network observability, and AI-generated network optimizations, powered by AI insights from a rapidly growing customer base.</p>


HPE Expands AI-Powered Automation, Introduces Monitoring For Third-Party Devices And End-User Experience

<p><i>First live deployment of CommScope's Full Duplex (FDX) DOCSIS Amplifier and Remote PHY Device Node in Comcast network</i></p>
<p><i>Milestone achievement is the result of multi-year joint development efforts of industry-leading new technology</i></p>
<p>Comcast and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.commscope.com%2F&amp;esheet=54126293&amp;newsitemid=20240924000466&amp;lan=en-US&amp;anchor=CommScope&amp;index=1&amp;md5=9d542ed7e6bc90cf5bfa2f32edc6637a">CommScope</a> announced today that for the first time CommScope's&#xAE; Full Duplex (FDX) DOCSIS&#xAE; amplifier is now live serving customers in Comcast's network. With the deployment of FDX amplifiers, Comcast will be able to seamlessly deliver multi-gig symmetrical services along with enhanced reliability, security and performance, to customers served by the vast majority of its current network architecture.</p>


COMM

Comcast And CommScope Notch Milestone Of First Live Deployment Of CommScope's Full Duplex DOCSIS Amplifier And Remote PHY Device Node In Comcast Network, In Bringing Next Generation Connectivity To Millions Across The U.S.

<p><strong>MSS: 163% &#x7C;</strong> <a href="https://www.benzinga.com//node/40990981">Maison Solutions shares are trading higher after the company reported a year-over-year increase in Q1 sales results.</a></p>
<p>&nbsp;</p>
<p><strong>LBRDA: 22% &#x7C; </strong><a href="https://www.benzinga.com//node/40991277">Liberty Broadband shares are trading higher after the company announced that it submit a counterproposal to charter for the proposed business combination.</a></p>
<p>&nbsp;</p>
<p><strong>SLXN: 81% &#x7C; </strong><a href="https://www.benzinga.com//node/40998946">Silexion Therapeutics Announced New Findings From Its Phase 2 Trial Of LODER In Patients With Non-resectable Locally Advanced Pancreatic Cancer (LAPC) Which Bear KRAS G12D Or G12V Mutation-Filing</a></p>


LBRDA

Merrill Lynch & Strategic Return Notes for Select 10 Index

SLXN

Market-Moving News for September 24th

<p><a href="https://www.globenewswire.com/Tracker?data=5jJBjFRY2ti1jM_WsXvT038ceHFS0RyecaUwaIkXpD7MRPvkXSokZbYZTICG0rSGM5lY3q3GTwvfHCjkv5A6hCqesfJh7kXCf-KWvesVXb4=">Enphase Energy, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, announced today the launch of its most powerful Enphase&#xAE; Energy System&#x2122; to-date, featuring the new IQ&#xAE; Battery 5P&#x2122; and IQ8&#x2122; Microinverters, for customers in India.<br /><br />&nbsp;</p>
<p>India's power grid is among the most challenging in the world, with frequent outages disrupting daily life for many households. The new Enphase Energy System transforms this situation by enabling uninterrupted, reliable backup power. Key components of the system include:</p>
<ul>
<li><strong>IQ Battery 5P:</strong> Enphase's most powerful <a href="https://enphase.com/en-in/store/storage/iq-battery-5p">home battery</a> yet, designed for modularity. Starting at 5 kWh, it can scale up to 40 kWh to meet varying home energy needs. With 3.84 kW continuous power and 7.68 kW peak power for short bursts, it enables homeowners to run even the most power-hungry appliances during outages. Built with advanced lithium iron phosphate (LFP) chemistry, the battery offers enhanced safety and significantly less maintenance compared to the widely used lead-acid batteries in India.</li>
<li><strong>IQ&#xAE; System Controller: </strong>The <a href="https://enphase.com/en-in/store/storage/iq-system-controller-3-int">controller (or backup switch)</a> isolates the home from the grid during outages, allowing seamless power supply from Enphase's solar and IQ Battery 5P systems. The transition is instant, so most homeowners won't even know there was an outage.</li>
<li><strong>IQ&#xAE; Microinverters:</strong> Homeowners can choose between IQ7 or IQ8 Microinverters. The IQ8HC&#x2122; and IQ8P&#x2122; Microinverters, <a href="https://investor.enphase.com/news-releases/news-release-details/enphase-energy-launches-iq8-microinverters-high-powered-solar">launched</a> in India last year, deliver peak AC output power of 384 W and 480 W, respectively, and seamlessly pair with solar panels up to 670 W DC. IQ8 Microinverters are grid-forming and feature Enphase's Sunlight Jump Start&#x2122;, allowing the system to restart using sunlight after a prolonged grid outage that drains the battery.</li>
</ul>


Global

ENPH

Enphase Brings IQ Battery To India, Offering Energy Independence Amid Outages

<p>Hampton Roads based TowneBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOWN#NASDAQ">TOWN</a>) and Village Bank and Trust Financial Corp. (NASDAQCM: VBFC) ("Village"), the parent company of Village Bank, today announced the signing of a definitive agreement and plan of reorganization pursuant to which TowneBank will acquire Village and Village Bank. The proposed transaction will enhance TowneBank's continued and growing presence in the Richmond MSA while providing opportunity for diverse revenue synergies with Towne Financial Services Group and strategic capital deployment.</p>


TOWN

TowneBank And Village Bank And Trust Financial Corp. Announce The Signing Of A Definitive Agreement And Plan Of Reorganization Pursuant To Which TowneBank Will Acquire Village And Village Bank

<p>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) reported quarterly losses of $(2.11) per share. This is a 90.21 percent increase over losses of $(21.55) per share from the same period last year.</p>


Earnings

CYTO

Altamira Therapeutics H1 2024 EPS $(2.11) Up From $(21.55) YoY

<p>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the upcoming late-breaking presentation related to ATR-04. The presentation by Dr. Mary Spellman will take place on Thursday, September 26, 2024, in a late-breaking oral session entitled "Development of a <i>Staphylococcus epidermidis</i> strain for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity" at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam.</p>
<p>ATR-04 is a live biotherapeutic product candidate consisting of an <i>S. epidermidis</i> strain that was isolated from a healthy volunteer and engineered to be safer by deleting an antibiotic resistance gene and engineering auxotrophy to control the growth of ATR-04. ATR-04 is in development for EGFRi-associated skin toxicity, which is caused by the suppression of skin immunity by EGFRis and subsequent inflammation and often elevated levels of IL-36γ and <i>S. aureus</i>. There are approximately 150,000 patients suffering from EGFRi-induced skin toxicity in the United States. Azitra has an active IND for a multicenter, randomized, controlled Phase 1/2 clinical trial of ATR-04 in patients with dermal toxicity due to EGFR inhibitors, and ATR-04 has received Fast Track designation from the FDA.</p>


AZTR

Azitra Announces Late-Breaking Presentation Related To ATR-04 At The EADV Congress

<p><i>-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA-</i><br /><br />&nbsp;</p>
<p><i>-Initial Label Would Include All Patients with Cardiomyopathy Associated with Duchenne Muscular Dystrophy-</i></p>
<p><i>-Rolling Submission Planned to Commence in October 2024-</i></p>
<p><i>-Internal GMP Manufacturing Established to Support BLA and Commercialization-</i></p>
<p><i>-Investor Webcast Today at 8:30 a.m. ET-</i></p>
<p>SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Dn3dPseyoYpJ2ydS9_fKGSY-L8y3j-58USJTWl-wU8dEA89PRS2JOkAnKJH6HgHxdaGntPImf1dAz10xwns5wWVF-ZkWxrG06hwj8W1ppJwm2PvCg47N6tUBYJpNjbU7XS0hd4gSdWmh8IMvOyGDntkraCOIdeb3sopV9B8ltkAflERhFEgZ-cOYB1pUfS5ZLkQMHm1eaJzMqxKEqbLfCNWU4f8b3VresJn-vaFF3zxYWk3KnleejbWgj8uh5dJg75izbevazWgAZXmJqhdVow==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today, following recent meetings with the U.S. Food and Drug Administration (FDA), its intent to file a Biologics License Application (BLA) based on existing cardiac and natural history data for deramiocel to treat all patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.</p>


CAPR

Capricor Therapeutics Announces Intent To File Biologics License Application For Full Approval Of Deramiocel For The Treatment Of Duchenne Muscular Dystrophy Cardiomyopathy

WIIM

Maison Solutions shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

<p>Benchmark  analyst Subash Chandra   maintains Sable Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) with a Buy and raises the price target from $24 to $37.</p>


Benchmark Maintains Buy on Sable Offshore, Raises Price Target to $37

<p><strong>NVIDIA Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares closed slightly<a href="https://www.benzinga.com/quote/NVDA"> higher on Monday</a>.</p>
<p>The company's CEO, <strong>Jensen Huang</strong>, has underscored the potential of artificial intelligence (AI) in reshaping India&#8217;s technological landscape, adding that it <a href="https://www.benzinga.com/news/24/09/40974645/nvidia-ceo-jensen-huang-meets-pm-modi-says-its-indias-moment-amid-ai-boom">was &#8220;India&#8217;s moment&#8221;.</a></p>
<p>Huang&#8217;s comments came following his meeting with Indian Prime Minister <strong>Narendra Modi</strong> during the latter&#8217;s three-day U.S. visit, which concluded on Monday. Huang was among the 15 tech leaders who had the opportunity to engage with the prime minister.</p>
<p>With the recent buzz around NVIDIA, some investors may be eyeing potential gains from the company's dividends. As of now, NVIDIA has a dividend yield of 0.03%, which is a quarterly dividend amount of 1 cent a share (4 cents a year).</p>
<p>To figure out how to earn $500 monthly from NVIDIA, we start with the yearly target of $6,000 ($500 x 12 months).</p>
<p>Next, we take this amount and divide it by NVIDIA's $1.00 dividend: $6,000 / $0.04 = 150,000 shares</p>
<p><strong>So, an investor would need to own approximately $17,439,000 worth of NVIDIA, or 150,000 shares to generate a monthly dividend income of $500.</strong></p>
<p><strong>Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.04 = 30,000 shares, or $3,487,800 to generate a monthly dividend income of $100.</strong></p>
<p>Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.</p>
<p>The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.</p>
<p>For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).</p>
<p>Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).</p>
<p>Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.</p>
<p><strong>NVDA Price Action:</strong> Shares of Nvidia gained 0.2% to close at $116.26 on Monday.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/09/40980672/top-3-financials-stocks-that-may-plunge-in-september">Top 3 Financials Stocks That May Plunge In September</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Long Ideas

Tech

How To Earn $500 A Month From NVIDIA Stock

<p>Across the recent three months, 7 analysts have shared their insights on Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.86, a high estimate of $21.00, and a low estimate of $12.00. Observing a downward trend, the current average is 8.86% lower than the prior average price target of $18.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727179279_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Crescent Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$16.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Crescent Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crescent Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Crescent Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Crescent Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRGY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Crescent Energy analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Crescent Energy</h2>
<p>Crescent Energy Co an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key proven basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non‐operated assets, mineral and royalty interests, and midstream infrastructure.</p>
<h3>A Deep Dive into Crescent Energy's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Crescent Energy displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>32.69%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Crescent Energy's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>5.75%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Crescent Energy's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.84%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.53%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Crescent Energy's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.18</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CRGY

Evaluating Crescent Energy: Insights From 7 Financial Analysts

<p>15 analysts have expressed a variety of opinions on Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Sunrun, revealing an average target of $23.3, a high estimate of $38.00, and a low estimate of $16.50. This current average has increased by 13.83% from the previous average price target of $20.47. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727179269_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Sunrun is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Corinne Blanchard</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$16.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sunrun. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sunrun compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Sunrun's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sunrun's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RUN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Sunrun analyst ratings.</strong></a></p>
<h2>Discovering Sunrun: A Closer Look</h2>
<p>Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.</p>
<h3>Sunrun: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Challenges:</strong> Sunrun's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-11.24%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Sunrun's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>26.72%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Sunrun's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.65%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Sunrun's ROA excels beyond industry benchmarks, reaching <strong>0.66%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Sunrun's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.25</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 15 Analyst Recommendations For Sunrun

<p>Ratings for TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated TransMedics Gr and provided 12-month price targets. The average target is $184.22, accompanied by a high estimate of $208.00 and a low estimate of $145.00. Observing a 29.6% increase, the current average has risen from the previous average price target of $142.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727179258_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive TransMedics Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$208.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$208.00</td>
<td>-</td>
</tr>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$169.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to TransMedics Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TransMedics Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of TransMedics Gr's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into TransMedics Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TMDX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on TransMedics Gr analyst ratings.</strong></a></p>
<h2>Discovering TransMedics Gr: A Closer Look</h2>
<p>TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.</p>
<h3>Financial Insights: TransMedics Gr</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> TransMedics Gr's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>117.87%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> TransMedics Gr's net margin excels beyond industry benchmarks, reaching <strong>10.67%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> TransMedics Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.98%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.65%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.72</strong>, TransMedics Gr faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TMDX

Expert Ratings For TransMedics Gr

<p>Analysts' ratings for First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for First Citizens BancShares, revealing an average target of $2212.5, a high estimate of $2300.00, and a low estimate of $2150.00. This current average has increased by 4.73% from the previous average price target of $2112.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727179244_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of First Citizens BancShares's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2150.00</td>
<td>$2450.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$2250.00</td>
<td>$1950.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2150.00</td>
<td>$1950.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$2300.00</td>
<td>$2100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to First Citizens BancShares. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Citizens BancShares compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of First Citizens BancShares's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of First Citizens BancShares's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FCNCA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on First Citizens BancShares analyst ratings.</strong></a></p>
<h2>Get to Know First Citizens BancShares Better</h2>
<p>First Citizens BancShares Inc is the bank holding company of First Citizens Bank &amp; Trust Company. FCB was founded as the Bank of Smithfield in North Carolina and has expanded through both de novo branching and acquisitions. FCB currently operates in nearly half of the continental United States, but principally takes deposits in the Carolinas. The bank's operations have historically been influenced by the Holding family, which has traditionally held executive and director positions, as well as controlling a large percentage of its outstanding stock. FCB provides a wide range of retail and commercial banking services, including traditional lending and deposit-taking, as well as trust and wealth management. FCB's main source of revenue is net interest income.</p>
<h3>Unraveling the Financial Story of First Citizens BancShares</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining First Citizens BancShares's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-4.27%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> First Citizens BancShares's net margin excels beyond industry benchmarks, reaching <strong>28.82%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> First Citizens BancShares's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>3.25%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.32%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> First Citizens BancShares's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.73</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FCNCA

Cracking The Code: Understanding Analyst Reviews For First Citizens BancShares

Notable earnings before Thursday's open

Precision BioSciences Q2 2024 Earnings Preview

Precision BioSciences GAAP EPS of $4.70 beats by $6.32, revenue of $49.9M beats by $41.58M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>With the market struggling amid rising recession fears, now may be the ideal time to consider <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. First, the sector itself is a financially lucrative one. Last year, the ecosystem <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reached a valuation of $1.55 trillion</a>. Between 2024 to 2030, the segment could expand at a compound annual growth rate (CAGR) of 13.96% to $3.88 trillion.</p>



<p>Along this line of thinking, the current market fallout makes biotech stocks all the more intriguing. No matter what, society will always push for solutions that address the human condition. From cancer to autoimmune diseases and other conditions and ailments, the search for effective treatments is a perpetual one. Not only that, a healthy society is an economically productive and efficient one.</p>



<p>Therefore, it&rsquo;s no surprise that government support and incentives underline various biotech-related initiatives. It&rsquo;s in all of our best interests to promote overall wellness. And in that sense, the narrative is recession resistant. With that in mind, below are biotech stocks you can now pick up on a relative discount.</p>



<h2>Crispr Therapeutics (CRSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/crispr_crsp1600-300x169.jpg" alt="CRISPR (CRSP) logo within a DNA sequence"><div>Source: Catalin Rusnac/ShutterStock.com</div></div><p>One of the most groundbreaking innovators among biotech stocks, <strong>Crispr Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/"><strong>CRSP</strong></a>) specializes in gene-editing therapies. Primarily, the company&rsquo;s CRISPR/Cas9 platform &ndash; a genome-editing technology that allows scientists to precisely alter DNA &ndash; may have the potential to cure various genetic disorders. Crispr aims to do so by essentially fixing faulty genes.</p>



<p>While CRSP stock is certainly enticing, its main challenge is profitability (or lack thereof). In the past year since the second quarter, Crispr posted an average loss per share of 81 cents. Now, in Q4 of last year, it posted earnings per share of $1.10, beating the expected loss of 7 cents. That demonstrates that Crispr has potential &ndash; it just needs to demonstrate this more often.</p>



<p>Right now, it&rsquo;s not the most attractively priced security, trading hands at 14.7x trailing-year sales. In contrast, the biotech sector&rsquo;s <a href="https://fullratio.com/ps-ratio-by-industry">average revenue multiple sits at 6.23x</a>. Still, in the past year, CRSP&rsquo;s average price-to-sales ratio stood at 27.09.</p>



<p>After a potentially rough outing in fiscal 2024, the following year could see <a href="https://finance.yahoo.com/quote/crsp/analysis">sales rise to $332.54 million</a>, with a blistering high-side estimate of $3.31 billion.</p>



<h2>Voyager Therapeutics (VYGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Focused on the development of gene therapies for severe neurological diseases, <strong>Voyager Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vygr-stock-quote/"><strong>VYGR</strong></a>) represents one of the top biotech stocks to consider. Its lead candidate is VY-TAU01, which is an anti-tau antibody program for the treatment of Alzheimer&rsquo;s disease. In its pipeline, it also features a gene therapy that addresses amyotrophic lateral sclerosis or ALS.</p>



<p>As with other biotech stocks, Voyager has trouble with generating consistent profitability. True, in Q4, the company posted EPS of $1.25. This dramatically exceeded the consensus target calling for a loss of 29 cents per share. However, the company has struggled in other quarters to print positive results. That also didn&rsquo;t change with the <a href="https://investorplace.com/earning-results/2024/08/vygr-stock-earnings-voyager-therapeutics-for-q2-of-2024/">latest Q2 results</a>.</p>



<p>At the moment, VYGR stock trades hands at 3.23x sales. While that seems undervalued, it&rsquo;s a deceptive figure since analysts are projecting that by the end of this year, sales may land at $48.51 million. If so, that would imply an 80.6% drop from last year&rsquo;s tally of $250.01 million.</p>



<p>However, because of the demand for treatment solutions for neurological diseases, VYGR stock is worth keeping on your watchlist.</p>



<h2>Sarepta Therapeutics (SRPT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/genetics-dna-flgt-1600-300x169.jpg" alt="a visualization of DNA in a vial. TSHA stock"><div>Source: Connect world / Shutterstock.com</div></div><p>A specialist in the field of precision genetic medicine, <strong>Sarepta Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/"><strong>SRPT</strong></a>) focuses on rare neuromuscular diseases. In particular, its RNA-targeted therapies and gene therapies provide hope for patients suffering from conditions such as Duchenne muscular dystrophy. While SPRT stock has been a strong performer this year, the market fallout has negatively impacted the company&rsquo;s valuation.</p>



<p>Curretnly, SRPT stock trades hands at 9.53x sales. That&rsquo;s a modest discount compared to the prior year&rsquo;s average multiple of 9.57x. Further, it&rsquo;s elevated compared to the industry average. However, it&rsquo;s worth pointing out that in fiscal 2024, analysts <a href="https://finance.yahoo.com/quote/srpt/analysis">project sales to hit $2.02 billion</a>. If so, this figure would represent a 62.6% lift from the prior year&rsquo;s haul of $1.24 billion. In addition, the high-side estimate calls for $2.32 billion.</p>



<p>Assuming a shares outstanding count of 94.52 million, SRPT is currently trading at around 5.73x projected high-side revenue. It&rsquo;s more than possible that Sarepta could hit that target considering that in fiscal 2025, the consensus view for sales calls for $3.27 billion. With so much excitement built into this space, SRPT ranks among the biotech stocks to buy.</p>



<h2>Regenxbio (RGNX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p>Another gene-therapy focused enterprise, <strong>Regenxbio</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgnx-stock-quote/"><strong>RGNX</strong></a>) is a clinical-stage biotech that utilizes a proprietary platform called NAV Technology. This platform enables Regenxbio to develop advanced therapeutic candidates for vexing conditions such as wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. It also features solutions for other conditions such as muscular dystrophy.</p>



<p>Coming upon a familiar theme among biotech stocks, Regenxbio has trouble with consistent profitability. In the past year since Q2, the company incurred a loss per share of $1.32. That said, analysts anticipated a loss of $1.34 during the same period. Therefore, the biotech managed to post a modest &ldquo;earnings&rdquo; surprise of 0.92%.</p>



<p>Right now, RGNX stock trades hands at 6.47x sales. That&rsquo;s roughly in line with the industry average. However, it&rsquo;s noticeably lower than the prior year&rsquo;s average multiple of 7.86x. Analysts see modest growth this year. However, in fiscal 2025, sales could soar to $249.2 million, a far cry from last year&rsquo;s print of $90.24 million.</p>



<h2>Blueprint Medicines (BPMC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/nktx_cancerresearch1600-300x169.png" alt="DNA strand and Cancer Cell Oncology Research Concept 3D rendering. LIXT Stock"><div>Source: CI Photos / Shutterstock.com</div></div><p>Another specialist in the field of precision medicine, <strong>Blueprint Medicines</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpmc-stock-quote/"><strong>BPMC</strong></a>) focuses on specific groups of cancers and rare diseases. It&rsquo;s potentially one of the groundbreaking biotech stocks thanks to the underlying targeted approach to cancer treatment. Essentially, Blueprint designs therapeutics based on the specific genetic mutations catalyzing the disease, potentially improving efficacy and reducing complications.</p>



<p>As with other biotech stocks, Blueprint is sporadic in terms of its bottom line. In the past year since Q2, the company posted an average loss per share of 86 cents. In Q1, it managed to deliver EPS of $1.40, far exceeding the expected loss of $1.66. However, investors will eventually want to see more of these positive figures.</p>



<p>Now, BMPC stock is risky, trading hands at 16.06x sales. That&rsquo;s a screaming hot premium. But to be fair, in the prior year, the average multiple stood at 21.41x. The kicker, though, is the fiscal 2024 forecast. Experts believe that revenue could jump to $491.86 million. If so, that would imply a near doubling from last year&rsquo;s print of $249.38 million.</p>



<h2>Precision BioSciences (DTIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/gene-edit-300x169.png" alt="An image of a scientist holding forceps, taking a piece of a DNA helix"><div>Source: Panuwach/Shutterstock</div></div><p>A biotechnology firm focused on the genome editing, <strong>Precision BioSciences</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtil-stock-quote/"><strong>DTIL</strong></a>) utilizes a proprietary platform called ARCUS to develop therapies for genetic diseases and cancer. Theoretically, this unique platform enables Precision to design highly specified genetic modifications. This process can potentially lead to more effective and safer therapies.</p>



<p>Unlike many other biotech stocks in its class, Precision has started to generate consistent profits. In the second half of 2023, the company incurred an average loss per share of $3.08. However, in the first half of this year, the average EPS stands at almost $3.19. In the past four quarters, the average EPS is 5 cents, yielding an earnings surprise of 139.8%.</p>



<p>Enticingly, shares trade hands at only 0.51x sales. What&rsquo;s more, in the prior year, the market accepted a multiple of 1.1x. Therefore, DTIL stock potentially has room to run. That&rsquo;s exactly what analysts are anticipating, projecting that fiscal 2024 sales may hit $72.47 million. That&rsquo;s up 48.7% from last year&rsquo;s tally of $48.73 million.</p>



<h2>Allogene Therapeutics (ALLO)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/allogene.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/allogene-300x169.jpg" alt="The logo for Allogene Therapeutics Inc (ALLO) is displayed on a building front."></a><p>A clinical-stage immuno-oncology firm, <strong>Allogene Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/allo-stock-quote/"><strong>ALLO</strong></a>) develops and commercializes genetically engineered allogeneic T-cell therapies for the treatment of cancer. Specifically, its platform targets pediatric and adult patients suffering from leukemia. According to its website, one of Allogene&rsquo;s core advantages is its scalable and efficient manufacturing process. This attribute enables potentially lifesaving care at reduced cost, holistically easing the burden of treatment.</p>



<p>Allogene isn&rsquo;t a profitable enterprise so it will require significant patience &ndash; more so than many other biotech stocks. In addition, the company doesn&rsquo;t generate much in terms of revenue. Last year, the company posted only $95,000 on the top line. What&rsquo;s worse, by the end of the current year, analysts believe that sales could dip to $50,000.</p>



<p>So, why bother with ALLO stock? Aside from the groundbreaking treatment potential, covering experts believe that by fiscal 2025, revenue could soar to $4.1 million. Further, the high-side estimate calls for $60.97 million.</p>



<p>Interestingly, assuming a shares outstanding count of 208.78 million, ALLO stock is trading at 8.53x projected high-side 2025 revenue. That&rsquo;s not bad considering the therapeutic potential.</p>



<p><em>On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>



<p><em>On the date of publication, the responsible editor held a LONG position in CRSP.&nbsp;</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/7-biotech-stocks-to-buy-for-their-game-changing-potential/">7 Biotech Stocks to Buy for Their Game-Changing Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Biotech Stocks to Buy for Their Game-Changing Potential

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL – Research Report). The associated pric...

Buy Rating on Precision BioSciences Highlighted by Promising Gene Editing Pipeline and Potential Hepatitis B Cure

<strong><i>The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCryst Pharmaceuticals (BCRX), and Precision BioSciences (DTIL) to their portfolio. Continue to read…</i></strong><br><br><p>The biotech industry is currently seeing a heightened demand for high-quality healthcare, innovative treatments, and advanced solutions, largely due to an aging population and escalating healthcare requirements. Given its rapid pace of innovation and promising growth potential, investing in select biotech stocks could be wise.</p>
<p>Amid this backdrop, fundamentally robust biotech stocks such as Fulcrum Therapeutics, Inc. (<a href="https://stocknews.com/stock/FULC/">FULC</a>), BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>), and Precision BioSciences, Inc. (<a href="https://stocknews.com/stock/DTIL/">DTIL</a>) could offer significant return potential owing to their dominance in high-demand areas and transformative treatments.</p>
<p>The biotechnology industry is experiencing rapid growth due to rising demands for personalized medicine, tailored treatments, and the approval of new drugs by the Food and Drug Administration (FDA).</p>
<p>This trend is highlighted in a survey conducted by GlobalData, which reveals that 44% of healthcare industry professionals globally are <a href="https://www.pharmaceutical-technology.com/analyst-comment/biotech-funding-optimism-rises/">optimistic or extremely optimistic</a> about the recovery of biotech funding in the next twelve months.</p>
<p>Incorporating Generative AI (GenAI) into biotechnology subjects is also revolutionizing the industry by enabling companies to derive valuable consumer insights, craft precise marketing strategies, and redefine healthcare engagements.</p>
<p>According to the McKinsey Global Institute, the integration of GenAI is anticipated to contribute an annual economic value of <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/early-adoption-of-generative-ai-in-commercial-life-sciences">$60 billion to $110 billion</a> for pharmaceutical and medtech firms.</p>
<p>Furthermore, according to a report by Precedence Research, the U.S. biotechnology market was valued at $246.18 billion in 2023 and is expected to expand at <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20U.S.%20biotechnology%20market%20size,with%20revenue%20share%20in%202023.">a CAGR of 11.6%</a>, reaching approximately $830.31 trillion by 2034.</p>
<p>Considering these factors, let's discuss the fundamentals of three high-potential <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks under $10, starting with #3.</p>
<p><strong>Stock #3: Fulcrum Therapeutics, Inc. (<a href="https://stocknews.com/stock/FULC/">FULC</a>)</strong></p>
<p>FULC is a clinical-stage biopharmaceutical company focused on treating genetically defined rare diseases. Its clinical product candidates, losmapimod and FTX-6058, are developed for facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease (SCD), respectively.</p>
<p>On May 13, FULC announced its <a href="https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-enters-collaboration-and-license-agreement">collaboration and license agreement</a> with Sanofi (<a href="https://stocknews.com/stock/SNY/">SNY</a>) for the development and commercialization of losmapimod, for the treatment of FSHD. SNY obtains exclusive commercialization rights for losmapimod outside of the United States under the agreement.</p>
<p>With the help of SNY's global reach, it could become easier for FULC to expand its pipeline and grab a stronger market presence in the FSHD treatment zone.</p>
<p>For the fiscal 2024 second quarter that ended on June 30, 2024, FULC's collaboration revenue increased significantly year-over-year to $80 million. The company's <a href="https://www.investopedia.com/terms/i/ifo.asp">income from operations</a> came in at $52.49 million, compared to a loss of $27.29 million in the previous year's quarter.</p>
<p>Also, its net income and net income per share were reported to be $55.41 million and $0.87, compared to a net loss and net loss per share of $23.78 million and $0.38, respectively.</p>
<p>Analysts expect FULC's revenue to increase 707.3% year-over-year to $7.03 million for the fiscal fourth quarter ending December 2024. Meanwhile, the consensus revenue estimate of $86.56 million for the fiscal year ending December 2024 reflects a significant year-over-year rise.</p>
<p>FULC's stock has gained 30.2% over the past three months and 96.4% over the past nine months to close the last trading session at $9.39.</p>
<p>FULC's bright outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.</p>
<p>FULC has a B grade for Value and Quality. It is ranked #26 among 341 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.</p>
<p><a href="https://stocknews.com/stock/FULC/">Click here</a> to access FULC's ratings for Growth, Stability, Momentum, and Sentiment.</p>
<p><strong>Stock #2: BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>)</strong></p>
<p>BCRX is a biotechnology company that develops oral small-molecule and protein therapeutics for rare diseases. Its products include ORLADEYO for hereditary angioedema prevention and RAPIVAB for acute uncomplicated influenza treatment in the United States.</p>
<p>On July 9, BCRX announced that its <a href="https://ir.biocryst.com/news-releases/news-release-details/orladeyor-berotralstat-approved-peru">oral, once-daily medication ORLADEYO&#xAE;</a> received approval from the General Directorate of Medicines, Supplies, and Drugs (DIGEMID) in Peru. The approval allows ORLADEYO&#xAE; to be used for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older.</p>
<p>Moreover, the approval in Peru adds to BCRX's established presence in the pan-Latin America region, following previous approvals in Chile, Argentina, Brazil, and Mexico. It signifies a significant milestone for BCRX, expanding its market and potentially attracting more customers seeking treatment for HAE.</p>
<p>BCRX's total revenues increased 32.5% year-over-year to $109.33 million for the fiscal 2024 second quarter that ended June 30, 2024.  Its adjusted income from operations also increased to $21.93 million compared to a loss of $7.86 million in the previous year's quarter.</p>
<p>In addition, as of June 30, 2024, BCRX's cash, cash equivalents and investments amounted to $336.34 million while total assets came in at $472.42 million.</p>
<p>BCRX's consensus revenue estimate of $113.89 million for the fiscal third quarter ending September 2024 reflects a year-over-year increase of 31.3%. Also, for the fiscal fourth quarter ending December 2024, BCRX's revenue is expected to increase by 26% from the prior year to $117.67 million.</p>
<p>In addition, BCRX has topped the consensus revenue estimates in all of the trailing four quarters, which is impressive.</p>
<p>Shares of BCRX have surged 31.3% in the past three months and 45.8% in the past nine months to close the last trading session at $8.05.</p>
<p>BCRX's robust outlook is reflected in its POWR Ratings. The stock has an overall rating of B, translating to Buy in our proprietary rating system.</p>
<p>BCRX has a B grade for Growth, Sentiment, Value, and Quality. It has ranked #17 out of 341 stocks in the Biotech industry.</p>
<p><a href="https://stocknews.com/stock/BCRX/">Click here</a> to access BCRX's ratings for Stability and Momentum.</p>
<p><strong>Stock #1: Precision BioSciences, Inc. (<a href="https://stocknews.com/stock/DTIL/">DTIL</a>)</strong></p>
<p>DTIL is an innovative gene editing company specializing in developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. The company's focus is on advancing gene edits and transformative treatments within these critical medical fields.</p>
<p>On August 9, DTIL announced <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-investigational-new-drug">U.S. Food and Drug Administration's (FDA) approval</a> for its partner TG Therapeutics, Inc. (<a href="https://stocknews.com/stock/TGTX/">TGTX</a>) to commence Phase I clinical trial of Azercabtagene Zapreleucel (azer-cel) for its Investigational New Drug (IND) Application for progressive forms of multiple sclerosis (MS).</p>
<p>As the company receives approvals for its drugs in the auto-immune disease treatment market, it ensures a stronger market presence and presents better growth prospects.</p>
<p>On July 1, DTIL announced its addition to the <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-its-addition-russell-microcapr">Russell Microcap&#xAE; Index</a>, a key benchmark utilized by investment managers and institutional investors for index funds. The inclusion could lead to heightened visibility globally, attracting potential investors and fostering further growth opportunities for the company.</p>
<div class="flex-1 overflow-hidden">
<div class="h-full">
<div class="react-scroll-to-bottom--css-ulgnp-79elbk h-full">
<div class="react-scroll-to-bottom--css-ulgnp-1n7m0yu">
<div class="flex flex-col text-sm md:pb-9">
<article class="w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]" dir="auto" data-testid="conversation-turn-17" data-scroll-anchor="true">
<div class="text-base py-[18px] px-3 md:px-4 m-auto md:px-5">
<div class="mx-auto flex flex-1 gap-4 text-base md:gap-5 lg:gap-6 md:max-w-3xl">
<div class="group/conversation-turn relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex-col gap-1 md:gap-3">
<div class="flex max-w-full flex-col flex-grow">
<div class="min-h-[20px] text-message flex w-full flex-col items-end gap-2 break-words [.text-message+&amp;]:mt-5 overflow-x-auto whitespace-normal" dir="auto" data-message-author-role="assistant" data-message-id="8fe0c70b-67a1-4de1-a838-d3c1def07b65">
<div class="flex w-full flex-col gap-1 empty:hidden first:pt-[3px]">
<div class="markdown prose w-full break-words dark:prose-invert dark">
<p>For the fiscal 2024 second quarter that ended June 30, DTIL's revenue increased 152.2% year-over-year to $49.90 million. Its operating income amounted to $24.15 million compared to a loss of $3.13 million in the previous year's quarter.</p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</article>
</div>
</div>
</div>
</div>
</div>
<p>Additionally, the company's net income and net income per share came out to be $32.75 million and $4.67 compared to a net loss and loss per share of $11.89 million and $3.13, respectively.</p>
<p>Analysts project DTIL to achieve $57.40 million in revenue for the fiscal year ending December 2024, reflecting a 17.8% year-over-year increase. Additionally, the company is expected to report an EPS of $2.10 for the period. Notably, DTIL has exceeded consensus revenue estimates in three of its last four quarters.</p>
<p>DTIL's shares marginally declined intra-day close the last trading session at $9.85.</p>
<p>The stock's positive fundamentals are reflected in its POWR Ratings. DTIL has an overall rating of B, which equates to a Buy in our proprietary rating system.</p>
<p>DTIL has an A grade for Sentiment and a B grade for Value. It is ranked #16 out of 341 stocks within the same industry.</p>
<p><a href="https://stocknews.com/stock/DTIL/">Click here</a> to access DTIL's ratings for Stability, Quality, Growth, and Momentum.</p>
<p><em><strong>What To Do Next?</strong></em></p>
<p>43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.</p>
<p><strong><a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt; </a></strong></p>
<p>&nbsp;</p>

<hr />
<p>BCRX shares were trading at $8.05 per share on Tuesday morning, down $0.18 (-2.19%). Year-to-date, BCRX has gained 34.39%, versus a 18.97% rise in the benchmark S&amp;P 500 index during the same period.</p>
<hr><div style="clear:both;"></div><br><h2>About the Author: Aanchal Sugandh</h2><br><img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;"><p>Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.</p><p><a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a></p>The post <strong><a href=https://stocknews.com/news/bcrx-fulc-dtil-tgtx-sny-3-high-potential-biotech-stocks-under-10/>3 High-Potential Biotech Stocks Under $10</a></strong> appeared first on <strong><a href=https://stocknews.com/>StockNews.com</a></strong>

3 High-Potential Biotech Stocks Under $10

The latest announcement is out from Precision BioSciences (DTIL). Precision BioSciences, Inc. recently announced the successful maturity of a $13 m...

Precision BioSciences Secures Funds, Bolsters Oncology Partnership

An announcement from Precision BioSciences ( ($DTIL) ) is now available. Precision BioSciences, a leading gene editing company, has announced adjus...

Precision BioSciences Reshuffles Clinical Leadership Team

ABEV

ABUS

ACIW

AGIO

ALGM

ALLO

ALNY

APLS

APPN

APTV

ATGFF

ATUS

AUPH

AXTA

BALL

BAND

BCRX

BIGC

BIIB

BIPC

BMWYY

BPMC

BRPHF

CAMT

CCRD

CPSH

CRIS

CROX

CRSP

CRTO

CWEN

DHLGY

DINO

DRVN

EVGO

EXLS

FTDR

FULC

GOOS

SRPT

VYGR

Press Releases

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Precision BioSciences to Participate in Upcoming August Investor Conferences

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Events

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Precision BioSciences

Precision BioSciences (DTIL) Forecast

Precision BioSciences (NASDAQ:DTIL) Stock, Quote.Headers.trade-ideas